MSD Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes

MSD, known as Merck & Co., Inc. (NYSE:MRK) in the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, MSD’s investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to MSD’s once-daily DPP-4 inhibitor, JANUVIA® (sitagliptin) 50 mg, which is the standard starting dose for sitagliptin in Japan.1 MSD presented these data on omarigliptin, which has been shown to produce sustained DPP-4 inhibition, at an oral session at the 50th European Association for the Study of Diabetes (EASD) Annual Meeting.

Toys“R”Us, Inc. Strengthens Global E-Commerce Presence with Launch of Dedicated Web Store in China, Mobile Shopping Capabilities Introduced in Additional International Markets

Toys“R”Us, Inc. today announced it has strengthened its global e-commerce capabilities with the launch of a dedicated web store, Toysrus.com.cn, in China. The addition of this site represents a significant step in the company’s plans to grow its presence with physical stores and online operations in Asia. The company has also announced the development of mobile-optimized sites and apps in 11 markets around the world, including Australia, Canada, France, Germany, Japan, Spain, and the U.K. In the coming months, it will introduce the same capabilities in Portugal, Austria and Switzerland, as well as the Netherlands, where it does not currently have a store presence.

CYA HOTBackup Now Available Through the EMC Select Program

CYA Solutions Group of enChoice today announced that its CYA HOTBackup™ solution will now be resold through the EMC Direct Sales and EMC Channel Partner networks worldwide utilizing the EMC Select Program. CYA HOTBackup enhances interoperability between EMC Documentum® and existing enterprise-wide backup systems by automating hot, consistent backups of the Documentum Platform.

Terumo BCT’s Mirasol® Pathogen Reduction Technology System Granted Authorization for Use in Austria

Terumo BCT’s customer, Europlasma GmbH, is the first blood center in Austria to receive authorization from AGES, the Austrian Agency for Health and Food Safety, to use the Mirasol Pathogen Reduction Technology System with platelets. The authorization enables the blood center to adopt an enhanced approach to blood safety, using the Mirasol system for all platelets collected for transfusion.